摘要
目的探讨应用利伐沙班预防髋关节置换术后深静脉血栓形成的临床价值。方法选择于2011年3月至2012年9月在本科行人工髋关节置换手术的患者81例85髋,随机分成利伐沙班组(41例43髋)和低分子肝素组(40例42髋)。在髋关节置换术后,低分子肝素组给予分子肝素钠4100IU/d皮下注射,持续用药2周;利伐沙班组给予利伐沙班片10mg/d口服,持续用药2周。于治疗第2周后采用彩色多普勒超声检查两组患者深静脉血栓的形成情况,并检测术前术后APTT、PT、PLT各项指标和记录术后引流量。结果低分子肝素组发生深静脉血栓5例(12.5%),利伐沙班组发生深静脉血栓2例(4.9%),两组深静脉血栓发生率比较差异有统计学意义(P<0.05)。两组术后引流量、血液指标比较无统计学差异,利伐沙班组无明显不良反应发生。结论利伐沙班能有效预防髋关节置换术后深静脉血栓形成,具有良好的安全性,值得临床推广。
Objective To investigate the clinical efficacy of rivaroxaban on preventing deep vein thrombosis（DVT）in postoperative hip arthroplasty.Methods 81 patients with hip arthroplasty by operation in our hospital from March 2011 to Spe.2012 were selected and randomly divided into two groups,rivaroxaban and low molecular weight heparin（LMWH）groups,40 cases in rivaroxaban group and 40 cases in LMWH group.The rivaroxaban group was given oral rivaroxaban 10 mg at postoperative 6 h,once a day for continuous 2 weeks.The LMWH group was given LMWH 4100IU/d with in postoperative 12 h,by subcutaneous injection for continuous 2 weeks.The DVT formation was detected by color Doppler ultra sound and compared between two groups after 2 week treatment.Results 5 case had DVT in the LMWH group with the occurrence rate of 12.5% and 2 cases had DVT in the rivaroxaban group with the occurrence rate of 4.9% ,showing statistical difference between the two groups（P 0.05）.The rivaroxaban group had no obvious adverse reactions.Conclusion Rivaroxaban can effectively prevent postoperative DVT in hip arthroplasty and has good security with less adverse reactions,which can be used in clinical practice.
出处
《中国现代药物应用》
2013年第11期13-14,共2页
Chinese Journal of Modern Drug Application
基金
沈阳医学院科研基金资助项目
关键词
利伐沙班
低分子肝素
髋关节置换
预防
深静脉血栓
Rivaroxaban
Low molecular weight heparin
Hip arthroplasty
Prevention
Deep vein thrombosis
